NasdaqCM - Nasdaq Real Time Price • USD Klotho Neurosciences, Inc. (KLTOW) Follow Compare 0.0549 +0.0049 +(9.80%) At close: January 24 at 4:00:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union SquareNEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200 investors. T Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of DirectorsNEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, Former Merck USA President Joins Klotho Neurosciences’ Board of Directors Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board ExpertiseNEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical indus Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor Discoverer of Klotho gene further strengths KLTO Scientific Advisory BoardNEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidatesNEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosc Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics DevelopmentNEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to gui